About Isera Lifesciences Limited
Data last updated:
Isera Lifesciences Limited is a public limited company based in Pune, Maharashtra, India. It operates in the application development and software solutions segment of the technology and IT services sector. It was incorporated on 27 January 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN L72200PN1993PLC252720. Its GSTIN is 36AACCL1189J1ZB (Telangana). The company holds 2 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 534920.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹8.41 Cr. It was formerly known as Aarya Consultants Private Limited and Fastrak Industries Limited. It is led by directors including Jayshree Babulal Jain (Managing Director) and Mangina Rao Srinivas.
Its last annual general meeting (AGM) was held on 26 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Pune, Maharashtra.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹1.36 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹27 Lakh (net margin 19.9%) and EBITDA of ₹28 Lakh (EBITDA margin 20.6%). The net worth stands at ₹8.25 Cr (up 8350% YoY). Total assets are valued at ₹9.91 Cr (up 556.3% YoY).
The company has about 1 employee on its provident fund (EPFO) records.
The company is associated with 1 brand: Covidh Technologies. As per MCA filings, the company has satisfied charges of ₹1.6 Cr on record. Court records list 3 cases involving the company, including 3 filed against it. The company has 18 deals on record (18 market trades); the latest was in April 2017. Its 4 peer companies in the Information Technology industry (Application Development), with the same principal business activity (other information & communication service activities) are compared by revenue, 3 larger and 1 smaller; the largest is Rishi Systems Private Limited. with revenue of ₹26.62 Lakh.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website covidh.com.
Company details
Name history
Isera Lifesciences has undergone 8 name changes throughout its history. The current legal name is Isera Lifesciences Limited.
| Company Name | Status |
|---|---|
| Isera Lifesciences Limited | Current |
| Aarya Consultants Private Limited | Previous |
| Fastrak Industries Limited | Previous |
| Lordven Technologies Limited | Previous |
| Lorden Technologies Limited | Previous |
| Fastrak Capitals Limited | Previous |
| Fastrak Capitals Private Limited | Previous |
| Aptus Industries Limited | Previous |
CIN history
Isera Lifesciences has 4 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L72200PN1993PLC252720, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L72200PN1993PLC252720 | Current |
| L45400AP1993PLC015306 | Previous |
| L72200TG1993PLC015306 | Previous |
| L67120AP1993PLC015306 | Previous |
| L72200AP1993PLC015306 | Previous |
Contact details
Isera Lifesciences Limited's registered office is in Pune, Maharashtra.
- Registered AddressOffice No A1 – 1202 12th Floor Boulevard Towers Phase 2, Cts No 11 Sadhu Vaswani Chowk Camp, Pune, Maharashtra, India – 411001
- IndustryInformation Technology, Application Development & Software Solutions
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Isera Lifesciences operates one associated brand: Covidh Technologies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| IT solutions are offered by Covidh Technologies across various sectors. | covidh.com |
Financials of Isera Lifesciences Limited
FY 2025-26 filings availableIsera Lifesciences Limited reported revenue of ₹1.36 Cr (up 403.7% YoY) for FY 2025-26.
Financial Highlights
FY 2018-19 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2018-19 | FY 2017-18 | FY 2015-16 | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 25.69 | 33.57 | 25.50 | 11.06 | 35.89 | 25.85 |
| Revenue growth | -23.5% | - | +130.6% | -69.2% | +38.8% | - |
| EBITDA | 0.49 | 0.46 | (13.08) | 0.77 | 0.53 | 3.10 |
| EBITDA margin | +1.9% | +1.4% | -51.3% | +7.0% | +1.5% | +12.0% |
| Profit before tax | (0.01) | 0.00 | (13.38) | 0.10 | 0.20 | 2.96 |
| Net profit | (0.03) | (0.01) | (0.02) | 0.11 | 0.12 | 1.91 |
| Net profit margin | -0.1% | -0.0% | -0.1% | +1.0% | +0.3% | +7.4% |
| EPS (₹) | 0.00 | 0.01 | 0.00 | 0.12 | 0.10 | 1.74 |
| Balance sheet | ||||||
| Total assets | 11.13 | 10.04 | 8.06 | 20.30 | 19.48 | 16.09 |
| Net worth | 0.48 | 0.53 | 0.55 | 13.97 | 13.84 | 13.74 |
| Total debt | 10.64 | 9.51 | 7.51 | 6.33 | 5.64 | 2.35 |
| Cash & bank | 0.43 | 0.01 | 0.04 | 0.05 | 0.02 | 0.08 |
| Net working capital | 10.24 | 9.43 | 7.38 | 7.92 | 7.62 | 4.04 |
| Cash flow | ||||||
| Cash from operations | (0.33) | (0.65) | 0.81 | 0.49 | - | (1.94) |
| Cash from investing | (0.38) | (0.16) | (0.40) | (1.16) | - | (7.44) |
| Cash from financing | 1.13 | 0.80 | (0.42) | 0.69 | - | 9.45 |
| Particulars | Jun 2019 | Mar 2019 | Sep 2018 | Mar 2015 |
|---|---|---|---|---|
| Revenue | 1.11 | 3.62 | 7.42 | 2.24 |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | (0.01) | 0.20 | 0.11 | 0.58 |
| EBITDA margin | -0.9% | +5.5% | +1.5% | +25.4% |
| Depreciation | 0.00 | 0.09 | 0.02 | 0.56 |
| Interest | 0.06 | 0.13 | 0.11 | 0.00 |
| Profit before tax | (0.07) | (0.02) | (0.02) | 0.02 |
| Tax | 0.00 | 0.01 | 0.00 | (0.04) |
| Net profit | (0.07) | (0.03) | (0.02) | 0.06 |
| EPS (₹) | (0.06) | (0.03) | 0.00 | 0.00 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.36 | 0.27 | 0.00 | 0.00 | 0.00 | 2.13 | 2.13 |
| Revenue growth | +403.7% | - | - | - | -100.0% | 0.0% | - |
| EBITDA | 0.28 | 0.15 | (0.09) | (0.11) | (0.11) | 1.94 | (0.05) |
| EBITDA margin | +20.6% | +55.6% | - | - | - | +91.1% | -2.4% |
| Profit before tax | 0.35 | 0.15 | (0.09) | (0.11) | (0.11) | 1.80 | (0.39) |
| Net profit | 0.27 | 0.13 | (0.09) | (0.11) | (0.11) | 1.78 | (0.41) |
| Net profit margin | +19.9% | +48.2% | - | - | - | +83.6% | -19.3% |
| EPS (₹) | 0.31 | 3.65 | (2.91) | (3.73) | (3.51) | 1.68 | (0.39) |
| Balance sheet | |||||||
| Total assets | 9.91 | 1.51 | (0.03) | 0.01 | 0.00 | 1.91 | 6.68 |
| Net worth | 8.25 | (0.10) | (0.22) | (0.12) | (0.01) | (0.11) | 0.11 |
| Total debt | 1.66 | 1.61 | 0.18 | 0.13 | 0.00 | 2.02 | 6.56 |
| Cash & bank | 2.87 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net working capital | 3.67 | 0.28 | (0.04) | 0.01 | (0.01) | 1.51 | 6.10 |
| Cash flow | |||||||
| Cash from operations | (5.35) | (1.40) | (0.06) | (0.12) | (0.30) | 4.45 | 0.97 |
| Cash from investing | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 |
| Cash from financing | 8.14 | 1.42 | 0.06 | 0.13 | 0.30 | (4.55) | (0.97) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.16 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.00 | 0.06 | 0.00 | 0.01 | 0.00 | 0.27 | 0.00 | 0.00 |
| Total expenses | 0.34 | 0.59 | 0.48 | 0.00 | 0.02 | 0.04 | 0.07 | 0.01 |
| EBITDA | (0.34) | 0.57 | (0.29) | 0.00 | (0.02) | (0.04) | (0.07) | (0.01) |
| EBITDA margin | - | +49.1% | -152.6% | - | - | - | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.34) | 0.63 | (0.29) | 0.01 | (0.02) | 0.23 | (0.07) | (0.01) |
| Tax | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2019 | Mar 2019 | Sep 2018 | Mar 2015 |
|---|---|---|---|---|
| Revenue | 1.11 | 3.62 | 7.42 | 2.24 |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | (0.01) | 0.20 | 0.11 | 0.58 |
| EBITDA margin | -0.9% | +5.5% | +1.5% | +25.4% |
| Depreciation | 0.00 | 0.09 | 0.02 | 0.56 |
| Interest | 0.06 | 0.13 | 0.11 | 0.00 |
| Profit before tax | (0.07) | (0.02) | (0.02) | 0.02 |
| Tax | 0.00 | 0.01 | 0.00 | (0.04) |
| Net profit | (0.07) | (0.03) | (0.02) | 0.06 |
| EPS (₹) | (0.06) | (0.03) | 0.00 | 0.00 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2015-16 | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|---|---|---|
| Revenue | 25.69 | 33.57 | 25.50 | 11.06 | 35.89 | 25.85 |
| Revenue growth | -23.5% | - | +130.6% | -69.2% | +38.8% | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 |
| Total expenses | 25.20 | 33.11 | 38.58 | 10.29 | 35.36 | 22.75 |
| Employee cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.67 | 0.58 |
| EBITDA | 0.49 | 0.46 | (13.08) | 0.77 | 0.53 | 3.10 |
| EBITDA margin | +1.9% | +1.4% | -51.3% | +7.0% | +1.5% | +12.0% |
| Depreciation | 0.12 | 0.19 | 0.14 | 0.66 | 0.31 | 0.19 |
| Interest | 0.38 | 0.27 | 0.16 | 0.01 | 0.02 | 0.02 |
| Profit before tax | (0.01) | 0.00 | (13.38) | 0.10 | 0.20 | 2.96 |
| Tax | 0.02 | 0.01 | 0.03 | (0.01) | 0.08 | 1.05 |
| Net profit | (0.03) | (0.01) | (0.02) | 0.11 | 0.12 | 1.91 |
| Net profit margin | -0.1% | -0.0% | -0.1% | +1.0% | +0.3% | +7.4% |
| EPS (₹) | 0.00 | 0.01 | 0.00 | 0.12 | 0.10 | 1.74 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2015-16 | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|---|---|---|
| Equity & liabilities | ||||||
| Share capital | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 | 10.60 |
| Reserves & surplus | (10.12) | (10.07) | (10.05) | 3.37 | 3.24 | 3.14 |
| Shareholders' funds (net worth) | 0.48 | 0.53 | 0.55 | 13.97 | 13.84 | 13.74 |
| Minority interest | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 0.00 | 0.00 | 1.37 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 10.64 | 9.51 | 6.14 | 6.33 | 5.64 | 2.35 |
| Total debt | 10.64 | 9.51 | 7.51 | 6.33 | 5.64 | 2.35 |
| Total liabilities | 11.13 | 10.04 | 8.06 | 20.30 | 19.48 | 16.09 |
| Assets | ||||||
| Gross block | 0.87 | 0.61 | 1.85 | 9.33 | 7.15 | 6.02 |
| Net block | 0.87 | 0.61 | 0.71 | 7.90 | 6.37 | 5.55 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 4.23 | 5.36 | 6.34 |
| Investments | 0.00 | 0.00 | 0.00 | 0.28 | 0.18 | 0.18 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 14.31 | 17.04 | 10.98 | 8.32 | 10.95 | 8.12 |
| Cash & bank balances | 0.43 | 0.01 | 0.04 | 0.05 | 0.02 | 0.08 |
| Loans & advances | 2.03 | 2.26 | 2.75 | 4.04 | 2.36 | 1.96 |
| Total current assets | 16.77 | 19.31 | 13.77 | 12.41 | 13.33 | 10.16 |
| Total current liabilities | 6.53 | 9.88 | 6.39 | 4.49 | 5.71 | 6.12 |
| Net working capital | 10.24 | 9.43 | 7.38 | 7.92 | 7.62 | 4.04 |
| Total assets | 11.13 | 10.04 | 8.06 | 20.30 | 19.48 | 16.09 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2015-16 | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|---|---|---|
| Opening cash | 0.01 | 0.02 | 0.05 | 0.02 | - | 0.01 |
| Net cash from operating activities | (0.33) | (0.65) | 0.81 | 0.49 | - | (1.94) |
| Net cash from investing activities | (0.38) | (0.16) | (0.40) | (1.16) | - | (7.44) |
| Net cash from financing activities | 1.13 | 0.80 | (0.42) | 0.69 | - | 9.45 |
| Net change in cash | 0.42 | (0.01) | (0.01) | 0.03 | - | 0.07 |
| Closing cash | 0.43 | 0.01 | 0.04 | 0.05 | - | 0.08 |
| Particulars | FY 2018-19 | FY 2017-18 | FY 2015-16 | FY 2014-15 | FY 2013-14 | FY 2012-13 |
|---|---|---|---|---|---|---|
| Growth | ||||||
| Sales growth | -23.5% | - | +130.6% | -69.2% | +38.8% | - |
| EBITDA growth | +6.5% | - | -1798.7% | +45.3% | -82.9% | - |
| PBT growth | +9997.0% | +9997.0% | - | -50.0% | -93.2% | +9997.0% |
| Net income growth | -200.0% | - | -118.2% | -8.3% | -93.7% | - |
| Revenue CAGR (3Y) | +32.4% | -2.2% | -0.5% | - | - | - |
| EBITDA CAGR (3Y) | -14.0% | -4.6% | - | - | - | - |
| Profitability & leverage | ||||||
| Net income margin | -0.1% | -0.0% | -52.6% | +1.0% | +0.3% | +7.4% |
| Return on capital employed | 0.0% | +1.4% | 0.0% | +0.7% | +1.2% | +27.9% |
| Return on net worth | 0.0% | +0.1% | 0.0% | +0.9% | +0.8% | +20.3% |
| Debt / equity | 19.95 | 17.94 | 0.95 | 0.43 | 0.29 | 0.12 |
| Long-term debt / equity | 15.69 | 14.64 | 0.84 | 0.43 | 0.29 | 0.12 |
| Interest cover | 102.70 | 100.00 | -1.21 | 9.09 | 9.09 | 0.69 |
| Efficiency & per share | ||||||
| Fixed asset turnover | 34.72 | 55.03 | 4.56 | 1.34 | 5.45 | 8.07 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 1.64 | 1.97 | 2.64 | 1.15 | 3.76 | 4.93 |
| EPS (₹) | 0.00 | 0.01 | 0.00 | 0.12 | 0.10 | 1.74 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 |
| Book value per share (₹) | 0.46 | 0.50 | 0.52 | 13.18 | 13.06 | 12.96 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.16 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.00 | 0.06 | 0.00 | 0.01 | 0.00 | 0.27 | 0.00 | 0.00 |
| Total expenses | 0.34 | 0.59 | 0.48 | 0.00 | 0.02 | 0.04 | 0.07 | 0.01 |
| EBITDA | (0.34) | 0.57 | (0.29) | 0.00 | (0.02) | (0.04) | (0.07) | (0.01) |
| EBITDA margin | - | +49.1% | -152.6% | - | - | - | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.34) | 0.63 | (0.29) | 0.01 | (0.02) | 0.23 | (0.07) | (0.01) |
| Tax | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.36 | 0.27 | 0.00 | 0.00 | 0.00 | 2.13 | 2.13 |
| Revenue growth | +403.7% | - | - | - | -100.0% | 0.0% | - |
| Other income | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 1.08 | 0.12 | 0.09 | 0.11 | 0.11 | 0.19 | 2.18 |
| Employee cost | 0.05 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.28 | 0.15 | (0.09) | (0.11) | (0.11) | 1.94 | (0.05) |
| EBITDA margin | +20.6% | +55.6% | - | - | - | +91.1% | -2.4% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.12 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.22 |
| Profit before tax | 0.35 | 0.15 | (0.09) | (0.11) | (0.11) | 1.80 | (0.39) |
| Tax | 0.08 | 0.02 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Net profit | 0.27 | 0.13 | (0.09) | (0.11) | (0.11) | 1.78 | (0.41) |
| Net profit margin | +19.9% | +48.2% | - | - | - | +83.6% | -19.3% |
| EPS (₹) | 0.31 | 3.65 | (2.91) | (3.73) | (3.51) | 1.68 | (0.39) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 8.41 | 0.32 | 0.32 | 0.30 | 0.30 | 10.60 | 10.60 |
| Reserves & surplus | (0.16) | (0.42) | (0.54) | (0.42) | (0.31) | (10.71) | (10.49) |
| Shareholders' funds (net worth) | 8.25 | (0.10) | (0.22) | (0.12) | (0.01) | (0.11) | 0.11 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 1.66 | 1.61 | 0.18 | 0.13 | 0.00 | 2.02 | 6.56 |
| Total debt | 1.66 | 1.61 | 0.18 | 0.13 | 0.00 | 2.02 | 6.56 |
| Total liabilities | 9.91 | 1.51 | (0.03) | 0.01 | 0.00 | 1.91 | 6.68 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.70 | 1.79 |
| Net block | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.62 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 1.20 | 0.31 | 0.00 | 0.00 | 0.00 | 2.91 | 8.58 |
| Cash & bank balances | 2.87 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Loans & advances | 0.25 | 0.00 | 0.05 | 0.05 | 0.00 | 1.15 | 1.27 |
| Total current assets | 4.32 | 0.33 | 0.05 | 0.05 | 0.00 | 4.06 | 9.86 |
| Total current liabilities | 0.65 | 0.05 | 0.09 | 0.04 | 0.01 | 2.55 | 3.76 |
| Net working capital | 3.67 | 0.28 | (0.04) | 0.01 | (0.01) | 1.51 | 6.10 |
| Total assets | 9.91 | 1.51 | (0.03) | 0.01 | 0.00 | 1.91 | 6.68 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Net cash from operating activities | (5.35) | (1.40) | (0.06) | (0.12) | (0.30) | 4.45 | 0.97 |
| Net cash from investing activities | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 |
| Net cash from financing activities | 8.14 | 1.42 | 0.06 | 0.13 | 0.30 | (4.55) | (0.97) |
| Net change in cash | 2.85 | 0.02 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 |
| Closing cash | 2.87 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +403.7% | - | - | - | -100.0% | 0.0% | - |
| EBITDA growth | +86.7% | +266.7% | +18.2% | 0.0% | -105.7% | +3980.0% | - |
| PBT growth | +133.3% | +9998.0% | +18.2% | 0.0% | - | +9998.0% | - |
| Net income growth | +107.7% | +244.4% | +18.2% | 0.0% | -106.2% | +534.2% | - |
| Revenue CAGR (3Y) | - | - | -100.0% | -100.0% | -100.0% | -58.1% | -53.6% |
| EBITDA CAGR (3Y) | - | - | - | +30.1% | - | +62.8% | - |
| Profitability & leverage | |||||||
| Net income margin | +19.9% | +48.2% | - | - | - | +83.6% | -19.3% |
| Return on capital employed | +5.7% | +14.8% | 0.0% | 0.0% | 0.0% | +18.8% | 0.0% |
| Return on net worth | +6.0% | +240.0% | 0.0% | 0.0% | 0.0% | +32.9% | 0.0% |
| Debt / equity | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.02 |
| Long-term debt / equity | 0.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.53 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.10 | -129.41 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.22 | 1.19 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 1.80 | 1.74 | 0.00 | 0.00 | 0.00 | 0.37 | 0.23 |
| EPS (₹) | 0.31 | 3.65 | (2.91) | (3.73) | (3.51) | 1.68 | (0.39) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 9.81 | (3.03) | (6.68) | (3.91) | (0.15) | (0.10) | 0.11 |
To see the full year-wise statements and ratios of Isera Lifesciences Limited, buy the company report.
Board of directors of Isera Lifesciences Limited
Isera Lifesciences has 8 current directors and 33 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mangina Rao Srinivas Also directs: Balaxi Pharmaceuticals Limited, Droneacharya Aerial Innovations Limited, TCC Concept Limited and 5 more | Director | 30 May 2025 | 1 Years 4 Months | Current |
| Jitendra Prabhakar Nene Also directs: Majine Systems Private Limited, Uberactive Ventures Private Limited, Cabcrazy Info Private Limited and 1 more | Director | 24 Oct 2024 | 1 Years 11 Months | Current |
| Jayshree Babulal Jain Also directs: Acrion Advisors LLP, Ascentedge Advisors LLP | Managing Director | 28 Aug 2024 | 2 Years 1 Months | Current |
| Rinku Saini Also directs: Abhinandan Enterprises Limited, Atma Industries Limited, Saptak Chem and Business Limited and 3 more | Director | 01 Aug 2025 | 1 Years 2 Months | Current |
| Pratap Dadasaheb Deshmukh Also directs: Isera Biological Limited, Saksham Aging Solutions Private Limited | Director | 02 Apr 2026 | 0 Years 6 Months | Current |
| Nandkumar Subhash Kadam Also directs: Isera Biological Limited | Director | 02 Apr 2026 | 0 Years 6 Months | Current |
Peer comparison
Isera Lifesciences Limited is compared with the 4 companies closest to it by revenue in the Information Technology industry (Application Development), with the same principal business activity (other information & communication service activities), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Isera Lifesciences Limitedthis company | ₹1.36 Cr (FY 2026) | ₹27 Lakh | 19.9% | 403.7% | Pune, Maharashtra, India | |
| Rishi Systems Private Limited. | ₹26.62 Lakh (FY 2019) | -24.0% | Bangalore, Karnataka, India | |||
| Shakuntalam Softwares Private Limited | ₹26.57 Lakh (FY 2025) | -9.0% | Delhi, India | |||
| Microbitz Solutions Private Limited | ₹26.54 Lakh (FY 2024) | -23.0% | Gurugram, Haryana, India | |||
| Webzone Technology Private Limited | ₹26.43 Lakh (FY 2019) | -50.0% | Ghaziabad, Uttar Pradesh, India |
To see the full peer comparison of Isera Lifesciences Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 01 Jul 2015 | 10583148 | Andhra Bank | ₹1.6 Cr | Satisfied |
To see the full charge records of Isera Lifesciences Limited, buy the company report.
Total charge records: 1 View all charges
Deals & funding
Isera Lifesciences Limited has 18 deals on record (18 market trades); the latest was in April 2017.
Deals on record (5 of 18)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2017 | Market trade | ₹3 Lakh | Seller: an individual |
| Mar 2017 | Market trade | ₹2.3 Lakh | Seller: an individual |
| Feb 2017 | Market trade | ₹9.4 Lakh | Buyer: 2 individuals Seller: 2 individuals |
| Feb 2017 | Market trade | ₹11.7 Lakh | Buyer: an individual Seller: 2 individuals |
| May 2014 | Market trade | ₹1.46 Cr | Buyer: Gajanan Enterprises Seller: Gajanan Enterprises, Setu Securities Private Limited , an individual |
To see the full deal history of Isera Lifesciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Isera Lifesciences Limited has 3 court cases on record: 3 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 2 | 2 | 0 |
| High courts | 1 | 1 | 0 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Hyderabad CCC, Telangana | Criminal complaint | Filed against the company by Ms Structures 18 Infra Tech Pvt Ltd | Disposed |
| District court, Hyderabad CCC, Telangana | Execution petition | Filed against the company by an individual | Disposed |
| Bombay High Court | Writ petition | Filed against the company | Disposed |
To see the full case history of Isera Lifesciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Isera Lifesciences Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Isera Lifesciences has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AACCL1189J1ZB | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Isera Lifesciences Limited, buy the company report.
Recent activity
Isera Lifesciences Limited has 36 board changes on record since 2014: 9 appointments and 27 cessations. The latest: Dhairyasheel Vasantrao Yadav was appointed as Director on 02 Apr 2026.
29 earlier events are in the company report.
Frequently asked questions
Isera Lifesciences is an active public limited company based in Pune, Maharashtra, India. The company works in application development and software solutions, within the information technology industry. It was incorporated on 27 January 1993 (33+ years old) and is registered under CIN L72200PN1993PLC252720. Listed on BSE: 534920.
Isera Lifesciences reported revenue of ₹1.36 Cr for FY 2025-26 (up 403.7% YoY) based on standalone financials.
Isera Lifesciences has 8 current directors:
- Jayshree Babulal Jain - Managing Director
- Mangina Rao Srinivas - Director
- Jitendra Prabhakar Nene - Director
- Rinku Saini - Director
- Pratap Dadasaheb Deshmukh - Director
- Nandkumar Subhash Kadam - Director
- Dhairyasheel Vasantrao Yadav - Director
- Ritu Dhanraj Garad - Director
The latest financial statements of Isera Lifesciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Isera Lifesciences is 36AACCL1189J1ZB, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Isera Lifesciences is L72200PN1993PLC252720. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Isera Lifesciences is a listed company as per MCA records. Its shares are listed on BSE (code: 534920).
Isera Lifesciences has 3 court cases on record: 3 filed against it. Most are in the district courts.
Isera Lifesciences was incorporated on 27 January 1993, making it 33+ years old. It is registered with the Registrar of Companies, Pune.
Isera Lifesciences has 18 deals on record (18 market trades); the latest was in April 2017.
The peers of Isera Lifesciences by revenue are Rishi Systems Private Limited, Shakuntalam Softwares Private Limited, Microbitz Solutions Private Limited, Webzone Technology Private Limited, all in the Information Technology industry (Application Development), with the same principal business activity (other information & communication service activities).